The “deeptech” and leading bioinformatics company Sequentia Biotech, member of CATALONIA.HEALTH, obtains a €10 million Series A investment, which is led by Seventure Partners, and co-invested by the EIC Fund. The investment will accelerate Sequentia Biotech’s mission to drive innovation in the field of omics.
Moreover, the funds will enable Sequentia Biotech to accelerate the market introduction and expansion of its flagship platform, MICK, and the scale up of its Best-in-Class Bioinformatics Enabling Technologies, driving its ambitious go-to-market strategy. This platform has the potential to redefine clinical decision-making, by integrating bioinformatics intelligence around omics into medical practice, biomedical and biopharma applications.
Walter Sanseverino, CEO and Co-Founder at Sequentia Biotech welcomed the funding stating, “We are delighted to announce this fundraising and our backing by Seventure Partners and the EIC Fund, two highly renowned venture capital investors with strong track records in supporting innovative companies in the life sciences sector. This investment will play a major role in advancing our mission to unlock the full potential of omics and accelerate the adoption of MICK by researchers and healthcare professionals globally.”
“We believe, we are on the brink of a new era in omics research and in our view, this investment is a signal of the market’s confidence in our vision and MICK‘s potential to disrupt the status quo,” said Riccardo Aiese Cigliano, Scientific Director and Co-Founder at Sequentia Biotech.
Comments